RNA Therapeutics

Arcturus Therapeutics Holdings Inc. announced it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET covering the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase deficiency and the company's mRNA liver therapeutics platform. The company will issue a press release summarizing the presentation prior to the call. Marshall Summar, M.D., a founding member and Executive Committee member of the NIH UCD Consortium and a recognized expert in rare diseases and OTC deficiency, will participate in the presentation. ARCT-810 is an intravenously administered investigational mRNA therapeutic designed to express normal functional OTC enzyme in the liver of individuals with OTC deficiency, and it holds Orphan Medicinal Product Designation and an approved pediatric investigation plan from the European Medicines Agency, plus Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. In Europe and the U.S., approximately 10,000 people have OTC deficiency.

On September 18, the Ministry of Industry and Information Technology, the National Development and Reform Commission, and eight other ministries jointly released the 15th Five-Year Plan for the Development of the Pharmaceutical Industry, proposing that by 2030, biopharmaceutical R&D and application will rank among the world's leaders, and the biopharmaceutical industry will accelerate its rise as a national emerging pillar industry. The plan sets 10 expected indicators covering industrial scale and efficiency, innovative development, enterprise cultivation, and cluster development, including operating revenue of pharmaceutical industrial enterprises above designated size exceeding 3.5 trillion yuan, an average annual growth rate of the innovative drug industry scale exceeding 20 percent, more than 5 products with global annual sales exceeding 1 billion US dollars, first-in-class innovative drugs accounting for more than 25 percent of the global total, more than 200 innovative medical devices launched, 50 pharmaceutical industrial enterprises with annual operating revenue exceeding 10 billion yuan, and 20 pharmaceutical industrial parks at the 100-billion-yuan level. Boosted by this news, the three major stock indices all rose more than 1 percent in early trading that day. Huatian Technology hit the daily limit up, with turnover of 6.065 billion yuan, nearly 1.47 million lots of sealed buy orders on the limit-up board, and nearly 3.3 billion yuan of main capital rushing in, ranking first in the A-share market. Zhou Sicong, fund manager of Ping An Pharmaceutical Select, believes innovative drugs are likely to become an important growth theme, and CITIC Securities said China's innovative drugs have entered a stage of global value realization. According to statistics from Securities Times Data Treasure, since September, Chengdu Leading Pharmaceutical, Asymchem Laboratories, Porton Pharma Solutions, and Hunan Warrant Pharmaceutical have led gains, all rising more than 10 percent, with Chengdu Leading Pharmaceutical up a cumulative 16.87 percent.

BioNTech reported detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. The shares traded around US$96.69, with a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. BioNTech now trades at roughly a 22% discount to analyst targets, with the most followed fair value view at $120.62 against the last close of $96.69. The company's pipeline includes multiple late stage Phase II and III trials for BNT327 and mRNA cancer immunotherapies in lung and breast cancers, supported by the planned CureVac acquisition. Risks to the bullish case include late stage oncology trial failures and prolonged COVID-19 vaccine demand weakness and related litigation.

Moderna and Merck reported positive results from the late-stage INTerpath-001 study of intismeran autogene (V940/mRNA-4157) in combination with Keytruda in patients with high-risk Stage IIB-IV melanoma whose tumors had been removed through surgery. The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, with the companies stating the improvements were statistically significant and clinically meaningful, though no numerical data were disclosed. INTerpath-001 marks the first positive phase III readout for an individualized neoantigen therapy and an mRNA-based cancer therapy, and five-year follow-up from the phase IIb KEYNOTE-942 study showed the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% versus Keytruda alone. Moderna and Merck are evaluating intismeran across nine phase II and phase III studies spanning multiple tumor types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma, while Moderna's broader pipeline includes separate mRNA-based cancer antigen therapies, a T-cell engager and a cell-therapy enhancer. Moderna shares have skyrocketed nearly 400% year to date, outperforming the industry's 7% growth, and the stock trades at 23.44 times forward 12-month sales versus the industry average of 1.90 times.

GSK plc plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The company reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to consolidate production in Canada, which it says can meet anticipated demand more sustainably and competitively, as falling demand for traditional egg-based flu vaccines has left GSK with more manufacturing capacity than it needs. The closure comes as GSK advances an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. GSK's vaccine business remains a significant earnings contributor, with second-quarter 2026 vaccine sales rising 8% to £2.3 billion, meningitis vaccines up 21%, Arexvy sales increasing by more than 100%, and Shingrix generating £0.9 billion. The company faces execution risk, as the mRNA flu candidate has only reached Phase III and opposition from the German union and works council could make the closure process more complicated or expensive.

Guobang Pharma announced that the pharmaceutical excipient "pegylated dimyristoyl glycerol (for injection)" produced by its wholly-owned subsidiary Zhejiang Guobang Pharmaceutical has passed the joint review and approval with the formulation by the Center for Drug Evaluation of the National Medical Products Administration, and its registration status has been changed to A. This product is a key functional excipient for mRNA vaccines and pharmaceutical formulations. This approval enables the product to meet the conditions for commercial production and supply to downstream customers, and the company expects it will have a positive impact on the market expansion of its pharmaceutical excipient business.

Merck & Co. reported second-quarter worldwide sales of $16.6 billion, with its oncology franchise led by intravenous Keytruda and the subcutaneous formulation Keytruda QLEX generating $8.4 billion in quarterly revenue. The pulmonary arterial hypertension treatment Winrevair surged 75% to reach $588 million, and management raised its full-year 2026 sales guidance to a range between $66.3 billion and $67.3 billion. The company faces the loss of exclusivity for Keytruda toward the end of 2028, pushing it to fund and acquire new pipeline assets, including a personalized mRNA cancer vaccine collaboration with Moderna. According to Insider Monkey's database, 101 hedge funds held a stake in the company during the second quarter, up from 98 in the prior quarter, while short interest sits at just 0.99% of the float. Fisher Asset Management maintained the top position with 38.5 million shares, increasing its holdings by 46%.

GSK plc is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid-stage results in both younger and older adults. The mRNA-based candidate generated stronger immune responses than currently approved standard-dose flu vaccines in younger adults and approved high-dose vaccines in older adults, according to GSK. Its design also targets two important surface proteins on the influenza virus, haemagglutinin and neuraminidase, rather than focusing on one. GSK said the late-stage study will be the first for an mRNA seasonal flu vaccine designed to target both proteins, and the company believes this approach could improve protection and reduce transmission. GSK intends to begin the late-stage trial in September 2026, part of a wider effort to accelerate its pipeline that, following a portfolio review by CEO Luke Miels, includes plans to initiate more than 20 late-stage studies by the end of 2026 as the company prepares for approaching patent expirations.

Walvax Biotechnology announced on the evening of September 10 that its wholly owned subsidiary, Yuxi Walvax Biotechnology, received the Drug Registration Certificate for the COVID-19 mRNA Vaccine approved and issued by the National Medical Products Administration that day. The vaccine is the company's third-generation COVID-19 mRNA vaccine iteratively developed on its mRNA platform technology, with the antigen sequence designed based on the S protein of the Omicron JN.1 strain, for use in people aged 18 and above to prevent disease caused by SARS-CoV-2 infection. The announcement showed that the company's previously developed first-generation COVID-19 variant vaccine with an S protein chimera and the second-generation iterative vaccine targeting the Omicron XBB.1.5 variant jointly validated the mRNA platform technology. Following the approval of this vaccine, research and development and drug registration work related to the first- and second-generation vaccines concluded simultaneously. Citing data, the announcement said global sales of mRNA COVID-19 vaccines exceeded 6 billion US dollars in 2025, and the company stated that the approval of this vaccine is not expected to have a significant impact on this year's performance.

Moderna's stock surged as much as 160% after the company announced positive Phase 3 trial results for its mRNA-based personalized cancer vaccine, which significantly reduced the risk of melanoma recurrence in over 1,100 patients when combined with Merck's Keytruda. The trial was stopped early because the efficacy was so high that standard medical ethics required allowing control-group patients access to the treatment. Despite the jump, shares remain below previous highs, and analysts caution that scaling and pricing questions remain. Meanwhile, Target reported a 5.3% sales increase and a 100% jump in earnings per share, though much of that came from a one-time $994 million tariff refund. The company's digital sales grew 8.7%, and same-day deliveries rose 25%, but analysts question whether the turnaround can sustain the stock's 60% year-to-date gain. In AI news, OpenAI's 18% quarterly growth disappointed investors, while Anthropic more than doubled revenue, and both companies are racing toward IPOs.

Moonwalk Biosciences, a biotechnology company developing adipose-targeted RNA interference medicines for obesity and cardiometabolic diseases, announced the closing of an oversubscribed $70 million Series B financing. The round was co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures, and existing investors ARCH Venture Partners, Khosla Ventures, and Future Ventures. Proceeds will support advancement of Moonwalk's lead obesity candidate, MW101, into first-in-human clinical studies in late 2027, expand its pipeline of tissue-targeted siRNA medicines, and further advance its proprietary discovery platform. The company also appointed Dr. Stephen Djedjos as Senior Vice President of Clinical Development, bringing over 20 years of experience from roles at Kailera Therapeutics, Mineralys Therapeutics, Sana Biotechnology, Gilead Sciences, and Amgen. Moonwalk's platform, which exclusively licensed adipose-targeting chemistry from Suzhou Siran Biotechnology, aims to selectively deliver siRNA to adipose tissue to modulate novel pathways underlying obesity, with preclinical data showing robust weight and fat mass reductions while preserving lean muscle.

4BIO Capital has led an upsized and oversubscribed $33 million seed financing for Cloverleaf Bio, an RNA therapeutics company developing engineered tRNA-based cancer treatments. The round includes strategic investments from AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund, alongside Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge. The funds will support proof-of-concept studies in hepatocellular carcinoma and advancement of a colorectal cancer program. Cloverleaf's lead compound, CLB-001, has shown greater potency and selectivity for cancer cells over healthy tissue in preclinical studies, and retains activity in resistant cancer cell lines. The company, a Yale University spinout headquartered in New Haven, Connecticut, plans to advance its lead assets toward clinical testing.

Shares of Swiss pharmaceutical giant Novartis fell as much as 3.3% on Monday (Sept. 7) after its key drug designed to lower Lp(a) levels in the blood failed a final-stage trial. The failure casts doubt on this treatment approach and has led investors to turn their attention to and raise expectations for upcoming data from an RNA therapy trial. Late Friday (Sept. 4), Novartis announced that pelacarsen did not significantly reduce the risk of heart attacks and strokes in a large final-stage trial involving patients with high Lp(a) levels, a genetic risk factor for which there is no targeted treatment. Previously, analysts had forecast that if the drug succeeded, it could achieve peak annual sales of $3 billion to $6 billion. The failure also poses a greater challenge to rival drugmakers Amgen and Eli Lilly, which are also in final-stage trials of Lp(a)-lowering drugs. The situation also adds pressure to other drugs in the pipeline, particularly del-desiran, an experimental treatment for myotonic dystrophy type 1 (DM1), with trial results expected in the fourth quarter of this year. Analysts note that the muscular dystrophy drug needs to succeed in trials to justify the investment of up to $12 billion that Novartis spent to acquire the rights to this drug. However, Novartis is also scheduled to report results from a trial of remibrutinib, an anti-inflammatory drug for chronic hidradenitis suppurativa, later this year. This drug recently succeeded in a trial for multiple sclerosis patients, which may help support and cushion investor disappointment. Before the share price decline on Monday, Novartis shares had risen about a fifth since the start of the year, driven by market confidence in its new drug pipeline, despite the company facing pressure from patent expirations on older drugs.

Moderna has initiated a Phase 3 trial of its mRNA-based bird flu vaccine, advancing the program into late-stage testing with support from a major international partnership focused on pandemic preparedness. The company has committed to equitable global access, including reserved manufacturing capacity for low- and middle-income countries. This trial is part of Moderna's broader strategy to apply its mRNA platform beyond COVID-19, targeting emerging infectious diseases. The program is backed by CEPI's US$54 million support, and Moderna has pledged to allocate 20% of manufacturing to low- and middle-income countries. Investors should watch for tangible government or multilateral purchase commitments that may follow, as the company's market value stands at about $59.4 billion.

Arrowhead Pharmaceuticals presented detailed results from the Phase 3 SHASTA-3 and SHASTA-4 studies in 757 adults with severe hypertriglyceridemia, showing that four quarterly 25-mg doses of plozasiran reduced triglycerides by a median of 79% and 81% at Month 12, compared with about 27% for placebo. A prespecified pooled analysis found a 78% reduction in the rate of all acute-pancreatitis events, with a rate ratio of 0.22 and a 95% confidence interval of 0.07 to 0.67, but that translated to a 4.1% absolute risk reduction and a number needed to treat of 24 over one year. The company plans to submit a supplemental New Drug Application for the broader severe-hypertriglyceridemia population before the end of 2026, using a Priority Review Voucher. Plozasiran, marketed as REDEMPLO, is already FDA-approved for familial chylomicronemia syndrome, and the new data could support expanding its label. However, the absolute benefit is more modest in the overall population compared with the 34% absolute risk reduction seen in patients with prior pancreatitis, and the company reported a higher rate of worsening-glycemic-control adverse events in treated patients.

The U.S. FDA has approved Ionis Pharmaceuticals' Zanvastro (zilganersen) as the first treatment for Alexander disease, a rare neurological disorder affecting fewer than 1,000 people in the U.S. The drug, designed to reduce abnormal GFAP protein production, showed statistically significant improvement in gait speed in a pivotal study and is approved for both pediatric and adult patients. Ionis plans to commercialize Zanvastro independently in the U.S., marking a key step in its strategy to launch wholly owned neurology medicines, while Recordati holds rights outside the U.S. Analysts at William Blair estimate peak annual sales of approximately $295 million, though the small patient population and complex administration may limit uptake. The approval validates Ionis' RNA-targeting platform and strengthens its neurology portfolio, which includes Spinraza, Wainua, and Qalsody.

GSK plc announced it will advance its mRNA-based seasonal influenza vaccine candidate into Phase III development, following positive Phase II results showing higher immune responses compared with standard-dose and high-dose flu vaccines in younger and older adults, respectively. The company plans to start the Phase III efficacy study in September 2026, which will be the first study of an mRNA flu vaccine designed to target both haemagglutinin and neuraminidase, potentially improving protection against illness and transmission. The FDA has granted Fast Track designation for the candidate. Year to date, GSK stock has risen 6.1%, while rival Moderna's shares jumped nearly 10% on the news, as investors viewed it as platform validation rather than a threat to its recently approved mRNA flu vaccine, mFlusiva.

Merck & Co., Inc. and Moderna, Inc. announced that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer therapy, potentially opening a new treatment class across multiple tumor types within the broader INTerpath clinical program. The success reinforces Merck's oncology leadership and could strengthen the short-term catalyst around pipeline conversion, while the biggest risk remains concentration in Keytruda and whether new launches can realistically fill that future revenue gap. Merck's raised 2026 sales guidance to US$66.3 billion to US$67.3 billion highlights how management already expected growth from multiple new products before factoring in this Phase 3 mRNA melanoma readout. Merck's narrative projects $74.9 billion revenue and $22.0 billion earnings by 2029, requiring 4.0% yearly revenue growth and a roughly $18.8 billion earnings increase from $3.2 billion today, with forecasts yielding a $136.85 fair value, a 9% downside to its current price.

Merck and Moderna announced a significant breakthrough in melanoma treatment, as their jointly developed mRNA cancer vaccine met the primary goal in its first Phase 3 trial, significantly extending the period patients lived without melanoma recurrence when combined with Merck's Keytruda compared to Keytruda alone. Following the announcement on Aug. 19, Moderna's shares surged nearly 177%, while Merck rose 12.60%. The global melanoma therapeutics market, estimated at $5.83 billion in 2024, is projected to reach $10.27 billion by 2030, with immunotherapy as the fastest-growing segment. Barclays analysts estimate the vaccine could generate up to $3 billion in annual melanoma-related sales by 2035. Investors seeking exposure may consider healthcare ETFs holding these stocks, such as the iShares Genomics Immunology and Healthcare ETF, where Moderna holds an 8.85% weight, and the VanEck Pharmaceutical ETF, where Merck holds a 10.94% weight.

Moderna led the S&P 500 in August after reporting promising results from a late-stage trial of a personalized mRNA cancer vaccine co-developed with Merck, according to CNBC. The data challenged years of skepticism about the company's mRNA technology following the decline of its Covid-19 vaccine business. Enterprise software stocks accounted for many of the index's other top performers, including Palantir, Veeva Systems, Salesforce, and ServiceNow, which had been under selling pressure due to AI concerns and large short positions held by the leveraged hedge fund Situational Awareness. When the fund was forced to unwind its trades in late July, those shorts became a tailwind for the stocks. Situational Awareness, run by Leopold Aschenbrenner, peaked at $45 billion in assets and lost roughly $35 billion after margin calls from prime brokers Bank of America, Goldman Sachs, and JPMorgan Chase forced a distressed sale to Ken Griffin's Citadel. Salesforce bounced back after better-than-expected quarterly results, while ServiceNow gained on AI integration, and Veeva Systems climbed as the anticipated AI threat failed to materialize. Outside software, Newmont benefited from gold price recovery, Coinbase rose with cryptocurrencies, and Super Micro Computer and Sandisk surged on AI memory demand. Moderna also raised $2 billion through convertible senior notes due 2032, earmarked for its cancer vaccine business, after its stock surged 177% on Aug. 19, adding $44.5 billion to its market capitalization in a single session.

GSK plc plans to launch a Phase 3 clinical trial in September for its experimental mRNA seasonal influenza vaccine after mid-stage data showed superior immune responses compared to licensed vaccines. The candidate, FLUm3HA.b-3NA, targets both haemagglutinin and neuraminidase surface antigens, a first for an mRNA flu vaccine. In the Flu-028 trial involving 971 adults, the vaccine generated higher immune responses against every tested strain than standard and high-dose inactivated vaccines, with acceptable safety. The U.S. Food and Drug Administration granted Fast Track designation in July 2026. GSK shares rose 0.46% to $50.48 in premarket trading.

Moderna Inc. saw its share price soar 156 percent in August, making it the highest-gaining stock for the month, driven primarily by strong clinical trial results for its melanoma therapy candidate and supported by a recent regulatory approval for its updated COVID-19 vaccines. The company, in partnership with Merck, is developing a treatment for melanoma combining mRNA-4157 with Keytruda; the phase 3 trial met its primary endpoint of recurrence-free survival and the key secondary target of distant metastasis-free survival, marking the first positive readout from a phase 3 trial for a combination of individualized neoantigen therapy and mRNA-based cancer therapy, and the first to show a clinically meaningful improvement over Keytruda alone. The US alone is expected to see 112,000 new melanoma cases this year, with 8,500 deaths, and globally 330,000 cases were diagnosed in 2022. The rally was also supported by the FDA's approval of Moderna's biologics license application for the 2026-2027 formulas of Spikevax and mNEXSPIKE vaccines, with Spikevax approved for individuals aged 6 months to 64 with at least one underlying condition and all adults 65 and older, and mNEXSPIKE approved for those 12 to 64 with high-risk conditions and all adults 65 and older. Hedge fund conviction strengthened in the second quarter, with 49 funds holding positions, down from 52, but their combined holdings increased 10 percent to $1.5 billion from $1.4 billion quarter-on-quarter.

Alnylam Pharmaceuticals presented new analyses at the European Society of Cardiology Congress in Munich supporting the use of Amvuttra across a range of transthyretin amyloidosis patients, including those already on Pfizer's tafamidis, and reported encouraging subgroup findings for its experimental hypertension drug zilebesiran. In the Phase 3 HELIOS-B study, 259 of the 654 treated patients were taking tafamidis at baseline, and Amvuttra's effect on the composite of death and recurrent cardiovascular events appeared consistent regardless of tafamidis use. Patients on Amvuttra also showed better preservation of walking ability and a 25% less deterioration in a composite measure of physical and mental function, with a 52% reduction in the risk of decline on that measure. A pooled analysis of 1,402 patients from four Phase 3 studies of Amvuttra and Onpattro showed consistent effects in women and men across cardiac and neurological forms of the disease. For zilebesiran, a post hoc subgroup analysis from the Phase 2 KARDIA-3 study showed larger systolic blood pressure reductions in high-risk patients with uncontrolled hypertension on a diuretic and at least one other drug, with effects extending across day and night; these findings are exploratory, and the drug's value depends on the ongoing Phase 3 ZENITH cardiovascular outcomes trial.

The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna and Merck announced on August 19 that their tailored mRNA cancer treatment was successful in a late-stage trial, significantly improving recurrence-free survival and distant metastasis-free survival compared with Keytruda alone in a study of over 1,100 patients. The Phase 3 trial, dubbed INTerpath-001, tested an individualized cancer vaccine called intismeran autogene in combination with Merck's blockbuster immunotherapy Keytruda in patients with completely resected stage IIB-IV melanoma. The trial achieved both its primary goals, recurrence-free survival, and a critical secondary target, distant metastasis-free survival, when compared to Keytruda alone. The companies stated that no new safety signals arose throughout the trial, and that the results expanded on previous Phase 2b data showing that the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to Keytruda alone. Personalized neoantigen vaccines have been considered as a cancer treatment concept for many years, but this is the first randomized Phase 3 experiment to definitely confirm their effectiveness. Moderna shares rose around 177% on the day of the news, adding approximately $45 billion to the company's market capitalization, while Merck posted a more modest but still significant 12% single-day rise. More broadly, roughly two-thirds of health-care stocks in a broad screen of over 100 names were higher on the week, with pharmaceutical and life-sciences names such as IQVIA, Danaher, and Thermo Fisher among the sector's other leaders, indicating that the rally is the result of renewed enthusiasm for the industry instead of a single-stock event.

Moderna received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant, as well as mFlusiva, its first mRNA-based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark the first FDA-authorized mRNA flu shot for older adults. The company, a US-based biotechnology firm developing messenger RNA medicines, sees these approvals as reinforcing its regulatory momentum and diversifying its respiratory offerings against competitors like Pfizer and Novavax in COVID and Sanofi and GSK in flu. However, analysts note that respiratory shots still depend on annual uptake, pricing, and pharmacy stocking, so the key question is how far these launches reduce reliance on a narrow set of seasonal products.

Frontier Biotech released its 2026 semi-annual report, achieving total operating revenue of 313 million yuan in the reporting period, a year-on-year surge of 434.27%, with net profit attributable to the parent company of 149 million yuan. Revenue mainly came from small nucleic acid technology licensing cooperation and sales of the core product Aikening. The company's small nucleic acid pipeline made key progress, with three dual-target candidate drugs FB7011, FB7023, and FB7033 advancing IND-enabling studies, while the single-target product FB7013 has received clinical trial approval and begun Phase I subject enrollment. The company reached a global licensing agreement with multinational pharmaceutical company GSK with a total deal value exceeding 1 billion US dollars, and the upfront payment and some milestone payments have been received. In addition, Vaconvir completed online sales coverage in 31 provincial-level administrative regions nationwide, the CDMO business signed orders for three new projects, and the loxoprofen sodium hot-melt adhesive patch FB3002 obtained a drug registration certificate in August 2026.

Arrowhead Pharmaceuticals, Inc. (ARWR) reached a major European milestone on August 17 when it announced the availability of REDEMPLO for adults with Familial Chylomicronemia Syndrome (FCS) in Germany, following European Commission authorization in June 2026. The drug is now listed in the Lauer-Taxe database for prescribing and reimbursement, and can be prescribed once every three months based on clinical symptoms or genetic tests. This launch expansion comes shortly after Arrowhead reported its fiscal Q3 2026 financial results on August 4, with quarterly revenue surging 171% year-over-year to $75.3 million, beating Wall Street expectations of $52.7 million, driven by collaboration income and doubling REDEMPLO U.S. prescription volume. Net loss widened to $194.2 million ($1.36 per share) due to R&D and commercial launch investments, but total cash resources remained strong at $1.56 billion. On August 6, H.C. Wainwright raised its price target on Arrowhead to $120 from $115, reiterating a Buy rating, citing a one-quarter pull-forward in the plozasiran launch timeline for severe hypertriglyceridemia (SHTG) and a new partnership with Madrigal. The bull case is supported by pivotal Phase III efficacy, durable reductions in triglycerides and acute pancreatitis events, and a $1.57 billion cash balance, while the bear case centers on persistent unprofitability, with quarterly operating losses of $170.1 million in Q3, and the commercial ramp remains unproven, with REDEMPLO generating just $2.4 million in early sales. Investors should watch the full presentation of SHASTA data at the ESC Congress on August 30 and the planned sNDA filing for plozasiran before year-end 2026, alongside initial REDEMPLO reimbursement adoption metrics in Germany.

Pfizer and BioNTech have received U.S. FDA approval for their updated mRNA COVID-19 vaccine, COMIRNATY XFG, for the 2026-27 season. The shot targets the XFG variant and is indicated for individuals aged five to 64 with at least one underlying condition that puts them at high risk for severe outcomes from the virus, as well as for all adults aged 65 and older.